Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old.
- You have triple-negative breast cancer that is confirmed by a biopsy or other test.
- Your cancer has gotten worse or come back after at least one round of systemic therapy (like chemo) for advanced disease, or within 6 months after finishing post-surgery chemo.
- Your tumor cells test positive for a protein called AXL (from a fresh or stored tissue sample).
- You have at least one tumor that can be measured on a scan (like CT or MRI).
- You are able to do daily activities with little or no help (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.